Question

Difficulty: HardHematology and Oncology

The triage nurse calls a physician to evaluate a newly arrived patient in the emergency department. The patient, a 34-year-old woman with no significant past medical history, describes a rapidly progressive, profound exhaustion over the last 72 hours, accompanied by intermittent episodes of confusion and 'purple spots' appearing on her legs.

Vital signs include a heart rate of 108/min, blood pressure of 142/88 mmHg, temperature of 37.8°C (100.0°F), and oxygen saturation of 98% on room air. Examination shows widespread lower extremity petechiae, mild scleral icterus, and temporal disorientation without focal neurological deficits.

Initial laboratory studies report:
TestResultReference Range
Hemoglobin7.6 g/dL12.0-15.5 g/dL
Platelet count18,000/mm³150,000-400,000/mm³
Leukocyte count8,400/mm³4,500-11,000/mm³
Creatinine1.3 mg/dL0.6-1.1 mg/dL
Total bilirubin3.2 mg/dL0.1-1.2 mg/dL
Indirect bilirubin2.8 mg/dL0.1-0.8 mg/dL
Lactate dehydrogenase (LDH)1,150 U/L140-280 U/L
Prothrombin time (PT)12 sec11-15 sec
Activated PTT (aPTT)30 sec25-40 sec

Based on the clinical presentation and initial laboratory data, arrange the following diagnostic and therapeutic steps in the strictly required chronological sequence to properly manage this patient's suspected hematologic emergency.

  1. 1Evaluate a peripheral blood smear to confirm the presence of microangiopathic hemolytic anemia
  2. 2Draw blood samples for ADAMTS13 activity and inhibitor testing
  3. 3Initiate urgent therapeutic plasma exchange (TPE) without waiting for specific assay results
  4. 4Monitor daily platelet counts and lactate dehydrogenase (LDH) levels

Answer

The correct sequence is: 1) Evaluate a peripheral blood smear to confirm MAHA, 2) Draw blood samples for ADAMTS13 activity, 3) Initiate urgent therapeutic plasma exchange (TPE), and 4) Monitor daily platelet counts and LDH levels.
In a patient presenting with the classic features of TTP—thrombocytopenia, microangiopathic hemolytic anemia (MAHA), and neurologic deficits without severe coagulation factor consumption (normal PT/aPTT)—the initial diagnostic step is confirming MAHA via a peripheral blood smear. Once clinically suspected, the absolute next critical step is drawing blood for ADAMTS13 activity and inhibitor testing. This MUST occur before any plasma is administered to avoid false-negative results. Immediately following the blood draw, empirical therapeutic plasma exchange (TPE) is initiated to remove the offending autoantibody and supply functional ADAMTS13. TPE should never be delayed pending assay results. Finally, disease response is tracked using daily platelet counts and LDH levels.

Step-by-Step Solution

1
Evaluate a peripheral blood smear
Confirmation of schistocytes
Establishes the presence of microangiopathic hemolytic anemia, which, alongside severe thrombocytopenia and normal coagulation studies, strongly suggests Thrombotic Thrombocytopenic Purpura (TTP).
2
Draw blood samples for ADAMTS13
Secures the unadulterated baseline enzyme level
Must be performed prior to any plasma infusion; donor plasma contains ADAMTS13 and will artificially normalize the patient's test results, obscuring the definitive diagnosis.
3
Initiate therapeutic plasma exchange (TPE)
Removal of ADAMTS13 inhibitors and replacement of functional enzyme
TTP is rapidly fatal if untreated. TPE must be started empirically immediately after blood draws, as ADAMTS13 results typically take days to return.
4
Monitor platelets and LDH
Assessment of disease activity and treatment efficacy
Guides the continuation, tapering, or modification of TPE and adjunctive immunosuppressive therapy.

Key Concept

The strict sequential management of suspected Thrombotic Thrombocytopenic Purpura (TTP) requires confirming MAHA, drawing an ADAMTS13 level prior to any plasma exposure, and immediately initiating empirical therapeutic plasma exchange.
Rate this question